Cluster analysis of antiphospholipid antibodies-associated adverse pregnancy outcome patients: based on a 13-years cohort study
- PMID: 37821708
- DOI: 10.1007/s10238-023-01195-x
Cluster analysis of antiphospholipid antibodies-associated adverse pregnancy outcome patients: based on a 13-years cohort study
Abstract
Antiphospholipid antibodies (aPLs) are the leading causes of adverse pregnancy outcomes (APOs). We conducted cluster analysis to identify distinct phenotypes among aPLs-associated APOs patients. This approach aims to facilitate risk stratification and improve pregnancy outcomes for obstetric APS. This was a retrospective study of persistent aPLs positive women cohort in Peking Union Medical College Hospital. Baseline demographic characteristics, clinical manifestation, previous APOs and antibodies profiles were included for hierarchical cluster analysis. Placentae from portions of patients were collected and performed the histopathologic diagnoses. Four clusters among 209 patients with 477 pregnancies were identified. Cluster 1 comprised patients with triple aPLs positivity and demonstrates a high incidence of gestational hypertension (34.92%, P < 0.05) and preterm delivery (20.63%, P < 0.05). Patients in cluster 2 were characterized by lupus anticoagulant (LA) positivity, with high risk of whole gestational APOs. Cluster 3 included patients with isolated aPLs-IgM isotype combined with early miscarriage (60.92%, P = 0.016). Patients in cluster 4 majorly presented aPLs-IgG isotype combined with placenta insufficiency (22.73%). During the follow-up, the live birth rate in cluster 1 and 2 was only 69.20%. Placenta pathology revealed the most severe impairment within cluster 1, whereas clusters 3 and 4 exhibited relatively milder damage. By cluster analysis, we identified four clinical subtypes of aPLs-associated APOs patients. Patients with triple antibodies or high-risk lupus characteristics were prone to occurred gestational hypertension and premature delivery. Isolated LA or aCL/aβ2GPI positivity were found to be more frequently associated with early-stage fetal loss.
Keywords: Adverse pregnancy outcome; Antiphospholipid antibody; Cluster analysis; Risk stratification.
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Similar articles
-
Analysis of Pregnancy Outcomes in Patients Exhibiting Recurrent Miscarriage With Concurrent Low-Titer Antiphospholipid Antibodies.Am J Reprod Immunol. 2024 Nov;92(5):e13940. doi: 10.1111/aji.13940. Am J Reprod Immunol. 2024. PMID: 39469745
-
Clinical characteristics and prognosis of patients with antiphospholipid antibodies based on cluster analysis: an 8-year cohort study.Arthritis Res Ther. 2022 Jun 11;24(1):140. doi: 10.1186/s13075-022-02814-w. Arthritis Res Ther. 2022. PMID: 35690831 Free PMC article.
-
Angiogenic markers could predict adverse pregnancy outcomes.Clin Exp Med. 2022 Nov;22(4):605-612. doi: 10.1007/s10238-021-00764-2. Epub 2021 Nov 6. Clin Exp Med. 2022. PMID: 34741679
-
Persistence of antiphospholipid antibodies over time and its association with recurrence of clinical manifestations: A longitudinal study from a single centre.Autoimmun Rev. 2022 Dec;21(12):103208. doi: 10.1016/j.autrev.2022.103208. Epub 2022 Oct 3. Autoimmun Rev. 2022. PMID: 36202304 Review.
-
Refractory obstetrical antiphospholipid syndrome: Features, treatment and outcome in a European multicenter retrospective study.Autoimmun Rev. 2017 Jul;16(7):730-734. doi: 10.1016/j.autrev.2017.05.006. Epub 2017 May 4. Autoimmun Rev. 2017. PMID: 28478081 Review.
Cited by
-
High Prevalence of Anti-Prothrombin IgM and IgG Autoantibodies in Women With Unexplained Recurrent Pregnancy Loss.Reprod Sci. 2024 Dec;31(12):3851-3857. doi: 10.1007/s43032-024-01725-2. Epub 2024 Oct 7. Reprod Sci. 2024. PMID: 39373852
-
Risk and protective factors of disease flare during pregnancy in systemic lupus erythematosus: a systematic review and meta-analysis.Clin Rheumatol. 2025 Mar;44(3):887-899. doi: 10.1007/s10067-025-07341-y. Epub 2025 Jan 27. Clin Rheumatol. 2025. PMID: 39870967
-
Impact of the 2023 ACR/EULAR Classification Criteria in Women with Primary Antiphospholipid Syndrome during Pregnancy.Diagnostics (Basel). 2024 Sep 28;14(19):2162. doi: 10.3390/diagnostics14192162. Diagnostics (Basel). 2024. PMID: 39410566 Free PMC article.
-
Risk stratification and subgroup analysis of systemic lupus erythematosus patients with pregnancy: based on a 13-year multicenter cohort study.Clin Rheumatol. 2025 Aug 12. doi: 10.1007/s10067-025-07552-3. Online ahead of print. Clin Rheumatol. 2025. PMID: 40797036
-
Predicting risk of the subsequent early pregnancy loss in women with recurrent pregnancy loss based on preconception data.BMC Womens Health. 2024 Jul 2;24(1):381. doi: 10.1186/s12905-024-03206-9. BMC Womens Health. 2024. PMID: 38956627 Free PMC article.
References
-
- Branch DW, Silver RM, Blackwell JL, Reading JC, Scott JR. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol. 1992;80(4):614–20. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous